Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — Q3 2022 Earnings Presentation
14 slides from Aquestive Therapeutics's earnings presentation, Nov 2, 2022
Slide 1: Q3 2022 Earnings Supplemental Materials
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. November 2022 Q3 2022 Earnings Supplemental Materials
Slide 2: Forward Looking Statement
Advancing medicines. Solving problems. Improving lives. ® Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,”
Slide 3: Q3 2022 Earnings: Key Messages
Advancing medicines. Solving problems. Improving lives. Q3 2022 Earnings: Key Messages AQST 109 Epinephrine Sublingual Film ❖ Reported positive results from EPIPHAST II Trial comparing AQST-109 to EpiPen® 0.3mg (single dose) and AQST-109 to epi 0.3mg intramuscular (IM) injection (repeat dose) ❖ Obta
Slide 4: Building Momentum Over the Last Days
Advancing medicines. Solving problems. Improving lives. 4 Building Momentum Over the Last 90 Days…. - Additions to Management Team And Board - Libervant FDA Tentative Approval Received SEPTEMBER - Allergy Scientific Advisory Board Established - Positive EPHIPHAST II Data - Libervant EU Licensing Dea
Slide 5: AQST 109: Epinephrine Sublingual Film
Advancing medicines. Solving problems. Improving lives. AQST 109: Epinephrine Sublingual Film 5
Slide 6: AQST-109: Epinephrine Sublingual Film
Advancing medicines. Solving problems. Improving lives. AQST-109: Epinephrine Sublingual Film First and only orally delivered epinephrine product candidate for the treatment of allergic reactions (type 1), including anaphylaxis, that would allow patients and their providers to: 6 Quickly deliver epi
Slide 7: AQST-109: Significant & Addressable Market Opportunity
Advancing medicines. Solving problems. Improving lives. AQST-109: Significant & Addressable Market Opportunity 7 Total Epinephrine Auto-Injector Market Rx’s: 2015-2021 (US) Allergists, Pediatricians, and Otolaryngologists (OTOs) prescribe roughly 1/2 of all EAI Rx’s • Large portion of annual Rx’s ar
Slide 8: EPIPHAST II: Topline Results
Advancing medicines. Solving problems. Improving lives. Treatment B a s e lin e A d ju s te d E p i C m a x 1 5 ( p g /m L ) 0 250 500 750 1000 1250 1500 1750 2000 IM 0.3 mg single (R1) EpiPen 0.3 mg single (R3) AQST-109 12 mg single (T1) EPIPHAST II: Topline Results Represents data from top-line re
Slide 9: EPIPHAST II: Time to Maximum Concentration (Tmax)
Advancing medicines. Solving problems. Improving lives. Baseline Adjusted Epinephrine Tmax EPIPHAST II Treatment B as el in e A d ju st ed E p i Tm ax ( m in u te s) 0 15 30 45 60 75 90 IM 0.3 mg single (R1) EpiPen 0.3 mg single (R3) AQST-109 12 mg single (T1) EPIPHAST II: Time to Maximum Concentrat
Slide 10: Manufacturing Operations
Advancing medicines. Solving problems. Improving lives. Manufacturing Operations 10
Slide 11: Manufacturing Operations
Advancing medicines. Solving problems. Improving lives. 11 Manufacturing Operations Manufacturing operations continues to meet the Company’s expectations and provides positive cash flow to the Company. - 10,000,000 20,000,000 30,000,000 40,000,000 50,000,000 60,000,000 Pharmfilm® Volume Q3 2020 Q4 2
Slide 12: 2022 Outlook
Advancing medicines. Solving problems. Improving lives. 2022 Outlook 12
Slide 13: 2022 Outlook
Advancing medicines. Solving problems. Improving lives. 2022 Outlook 2022 Outlook • Total revenues of approximately $46 to $49 million • Non-GAAP adjusted EBITDA loss of approximately $37 to $43 million 13
Slide 14: Thank You
Advancing medicines. Solving problems. Improving lives. Thank You
Aquestive Therapeutics — Q3 2022 Earnings Presentation on 6ix